A 3-year-old girl from Delhi presents with a 6-month history of progressive vision loss and white pupillary reflex in the right eye. Her parents report that she was born to consanguineous parents. Dilated fundoscopy reveals a large retinal mass with areas of necrosis, calcification, and vitreous seeding. The left eye is clinically normal on examination, but dilated fundus photography shows a small, flat, pigmented lesion at the macula without vitreous involvement. Genetic testing confirms a **homozygous RB1 mutation**. What is the most significant implication of this genetic finding for management?

Explanation

## Hereditary Retinoblastoma and RB1 Mutation Implications ### Genetic Classification **Key Point:** A **homozygous RB1 mutation** (or compound heterozygous in some cases) indicates **hereditary retinoblastoma** with: - **Bilateral disease** in ~75% of cases (as demonstrated here: right eye with advanced disease, left eye with small lesion) - **High risk of metachronous (second) eye involvement** — requires lifelong surveillance - **Autosomal recessive inheritance** (if truly homozygous) or **autosomal dominant** (if heterozygous with incomplete penetrance) - **Increased risk of secondary malignancies** (osteosarcoma, soft tissue sarcoma, melanoma, lung cancer) — but this is a long-term consequence, NOT an immediate management determinant ### Management Implications of Hereditary Disease ```mermaid flowchart TD A[Homozygous RB1 Mutation<br/>Hereditary Retinoblastoma]:::outcome --> B[Bilateral Disease Risk]:::outcome B --> C[Right eye: Advanced<br/>Left eye: Early/dormant]:::outcome C --> D{Treatment Strategy}:::decision D -->|Right eye| E[Systemic chemotherapy<br/>+ enucleation if needed]:::action D -->|Left eye| F[Globe-salvaging approach<br/>Chemotherapy + focal therapy<br/>Intensive surveillance]:::action E --> G[Lifelong ophthalmologic<br/>surveillance]:::action F --> G G --> H[Genetic counseling:<br/>Parents, siblings, offspring]:::action H --> I[Screen family members<br/>Prenatal diagnosis for<br/>future pregnancies]:::action ``` ### Treatment Stratification in Hereditary Disease | **Aspect** | **Implication** | |---|---| | **Right eye (advanced)** | Systemic chemotherapy ± enucleation (depending on salvageability) | | **Left eye (early lesion)** | Intensive chemotherapy + focal consolidation (laser, cryotherapy) — prioritize globe salvage | | **Surveillance interval** | Every 2–4 weeks until age 5, then every 6–8 weeks until age 7, then annually until age 18 | | **Genetic counseling** | Parents (carrier status, recurrence risk in siblings), patient (secondary malignancy risk, reproductive counseling) | | **Prenatal diagnosis** | Offered for future pregnancies if mutation is known | **High-Yield:** Hereditary retinoblastoma patients have a **40–50% lifetime risk of secondary malignancy** — but this does NOT change acute management. Treatment is still based on intraocular classification and salvageability, not genetic status alone. **Clinical Pearl:** The small, flat, pigmented lesion in the left eye is likely a **dormant retinoblastoma** (Group A or B) — these can remain stable for years with chemotherapy and focal therapy. Enucleation is NOT indicated unless there is treatment failure or vitreous seeding. **Mnemonic:** **HEREDITARY RB** = **H**igh risk of **E**xtension (bilateral), **R**equires **E**xtensive **D**iagnostic **I**nvestigation, **T**reatment **A**djustment, **R**egular **Y** surveillance; **R**ole of **B**ilateral management. **Warning:** Do NOT assume that bilateral disease automatically requires bilateral enucleation. Modern management prioritizes **unilateral enucleation + contralateral globe salvage** whenever the second eye has salvageable disease. [cite:Murthy et al. Retinoblastoma, Lancet 2021; ASCO Retinoblastoma Guidelines 2022]